AVENIO ctDNA Expanded Kit

Img1_ExpandedKit_770x530

The AVENIO ctDNA Expanded Kit is a next-generation sequencing (NGS) liquid biopsy assay with a 77 gene panel containing genes in U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers. The Expanded Kit is a pan-cancer assay that’s specially optimized for lung cancer and colorectal cancer (CRC).  


Features and Benefits of AVENIO ctDNA Expanded Kit 

  • Contains genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers
  • All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
  • Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
  • Includes reagents, bioinformatics and software
  • Streamlined, end-to-end workflow from extraction to analysis and reporting in five days


Product Highlights

Accurate detection of all four classes of mutations with high sensitivity and specificity2,3

  • >99% sensitivity for all four classes of mutations 
  • >99% positive predictive value (PPV) for indels, fusions and CNVs, and >98% PPV for SNVs


View performance data showing >99% sensitivity for all four classes of mutations using the AVENIO ctDNA Expanded Kit.

Figure1_Expanded_opt2_r



 

Profiling of a broad array of genes with a single assay kit

  • 77 assay targets in a single panel


A portfolio of NGS liquid biopsy assays  

The AVENIO ctDNA Expanded Kit is one of three assays in the AVENIO ctDNA assay portfolio. Learn more about the 17-gene AVENIO ctDNA Targeted Kit for guideline-driven tumor profiling or the 197-gene AVENIO ctDNA Surveillance Kit for longitudinal tumor burden monitoring

Specifications
 

Panel size 192 kb
Sample size 4 ml of plasma
cfDNA input 10-50ng
Reactions per kit 16
Turn-around time 5 days from extraction to results

References 

  1. National Comprehensive Cancer Network. www.nccn.org. October 15, 2016.
  2. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine. 2014;20(5):548–554. doi:10.1038/nm.3519.
  3. Data on file.

 

"AVENIO is a trademark of Roche. All other product names and trademarks are the property of their respective owners."